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Abstract. The pathophysiology of Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, and many others
converge at alpha-synuclein (-Syn) aggregation. Although it is still not entirely clear what precise biophysical processes act
as triggers, cumulative evidence points towards a crucial role for protein quality control (PQC) systems in modulating -Syn
aggregation and toxicity. These encompass distinct cellular strategies that tightly balance protein production, stability, and
degradation, ultimately regulating -Syn levels. Here, we review the main aspects of -Syn biology, focusing on the cellular
PQC components that are at the heart of recognizing and disposing toxic, aggregate-prone -Syn assemblies: molecular
chaperones and the ubiquitin-proteasome system and autophagy-lysosome pathway, respectively. A deeper understanding of
these basic protein homeostasis mechanisms might contribute to the development of new therapeutic strategies envisioning
the prevention and/or enhanced degradation of -Syn aggregates.
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INTRODUCTION24
Alpha-synuclein (-Syn) was first identified in25
human brain extracts more than 25 years ago [1, 2],26
and since then many physiological roles have been27
ascribed to this small protein. Although -Syn has no28
defined tridimensional structure in aqueous solution29
[3] and is soluble under most physiological condi-30
tions [4], it can adopt beta-strand rich conformations31
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Building 3215, 5th Floor, FB30, 9713 AV Groningen, Nether-
lands. Tel.: +31 50 3616143; Fax: +31 50 3616111; E-mail:
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favoring the formation of amyloid fibrils in several 32
neurodegenerative diseases, collectively known as 33
synucleinopathies [5–7]. For instance, -Syn aggre- 34
gates are found in distinctive neuronal structures 35
known as Lewy bodies (LBs) and Lewy neurites 36
(LNs) in idiopathic and familial forms of Parkinson’s 37
disease (PD) and dementia with Lewy bodies [8], 38
and in glial cytoplasmatic inclusions in multiple sys- 39
tem atrophy [9–12]. However, instead of being able 40
to adopt only one type of structure, recent studies 41
revealed that aggregated -Syn possess distinct con- 42
formations (polymorphs) with unique cytotoxicity 43
profiles [13–17]. This suggests that different synu- 44
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cleinopathies arise from distinct -Syn polymorphs,45
as indeed proposed by experiments in animal models46
[18, 19].47
Although the initial events leading to -Syn aggre-48
gation and toxicity in vivo are still poorly understood,49
several lines of evidence suggest that cellular pro-50
tein quality control (PQC) pathways play a central51
role in these processes. Among these are the molecu-52
lar chaperones and the two main protein degradation53
pathways, namely the ubiquitin-proteasome system54
(UPS) and autophagy-lysosome pathway (ALP) [20].55
Here, we review basic molecular and cellular princi-56
ples of -Syn aggregation and their connection with57
PQC components, with a special emphasis on the58
suppression of -Syn aggregation and/or toxicity by59
molecular chaperones.60
ALPHA-SYNUCLEIN STRUCTURE AND61
FUNCTION62
The N-terminal domain of -Syn contains sev-63
eral motifs with amphipathic properties allowing64
for interactions with membranes (binding to lipid65
vesicles) and that can serve in protein-protein inter-66
actions [21] (Fig. 1). The central portion (residues67
61 to 95) contains the non-amyloid-beta compo-68
nent of Alzheimer’s disease amyloid (NAC) motif69
[1], which is both sufficient and required for amy-70
loid formation [6, 22–24]. The C-terminal region71
has an important role in shielding the NAC motif72
from aggregation [6, 24]. Deletion of only the last73
10 amino acids is already sufficient to accelerate -74
Syn aggregation in vitro, and this effect is stronger75
upon larger C-terminal truncations up to amino76
acids 102–120 [24–26]. -Syn is subject to several77
post-translational modifications (PTMs), including78
N-terminal acetylation, ubiquitylation, SUMOyla-79
tion, nitration, and phosphorylation [27–32], with80
diverse consequences for its function and propen-81
sity to aggregate (detailed below). Several roles82
have been ascribed to -Syn, including facilitating 83
the assembly of N-ethylmaleimide-sensitive factor 84
attachment protein receptor (SNARE)-complexes at 85
presynaptic neuron terminals that mediate release of 86
neurotransmitters [33, 34], and induction of mem- 87
brane curvatures [35], among many others [36]. 88
SNCA MUTATIONS REVEAL UNIQUE 89
FEATURES OF -SYN TOXICITY AND 90
AGGREGATION 91
Two types of mutations in the SNCA gene have 92
been linked to autosomal dominant forms of PD, 93
highlighting distinct mechanisms by which -Syn 94
aggregation can be triggered: (i) increased gene 95
dosage and (ii) point mutations enhancing -Syn 96
aggregation propensity. The latter, including A30P 97
[37], E46K [38], H50Q [39, 40], G51D [41], and 98
A53T [42], A53V [43], and A53E [44] (see Fig. 1), 99
have been discovered by genetic screens in fami- 100
lies with hereditary PD and directly influence -Syn 101
aggregation to different extents and via discrete 102
pathways [45]. Mutants such as -SynA53T largely 103
enhance -Syn aggregation into fibrils [45, 46], most 104
likely by changing the conformational landscape 105
that-Syn populates towards aggregation-prone con- 106
formers, without disrupting vesicular interactions 107
[21]. In contrast, the A30P mutation does not 108
markedly modulate -Syn aggregation compared 109
to overexpression of -SynWT in cellular models 110
[46–48]. Instead, it abolishes -Syn interaction with 111
lipid vesicles both in vitro [21, 49] and in vivo [50], 112
which may lead to a buildup of cytosolic -Syn lev- 113
els, and eventually contributes to -Syn aggregation. 114
This implies that-Syn aggregation is also extremely 115
dependent on its concentration and can even be trig- 116
gered by the wild type protein [50, 51]. In fact, 117
familial PD cases caused by duplications or triplica- 118
tions of the SNCA locus have been identified [52–56], 119
Fig. 1. Domain structure of the human alpha-synuclein (-Syn) protein. -Syn comprises three basic domains: an N-terminal amphipathic
region, a central non--amyloid component (NAC) domain, and a C-terminal acidic domain. Seven membrane-interacting amino acid motifs
are also present in the first half of the protein. The region preceding the NAC domain concentrates all pathogenic -Syn mutations identified
so far. Numbers on the upper part of the structure refer to amino acid positions.
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with increased gene dosage correlating with earlier120
age at onset of disease [57].121
MODELLING -SYN AGGREGATION:122
SEEDED VERSUS NON-SEEDED123
CONDITIONS124
As for any aggregation-prone protein, -Syn125
molecules adopt conformations that allow the126
establishment of non-native interactions between127
molecules and their coalescence into thermody-128
namically unstable assemblies [58]. It is upon129
conformational transition to more regular and com-130
plementary interfaces [59] that stable seeds are131
generated, capable of acting as conformational tem-132
plate of the amyloid state [58]. In contrast, the highly133
stable preformed -Syn aggregates commonly used134
in studies grow by incorporation of -Syn molecules135
to their ends, as the binding of additional molecules136
to fibrillar ends generates an incorporation site for137
another molecule [58]. The spontaneous aggregation138
of -Syn into amyloid fibrils thus is a multi-step139
process during which various intermediates are gen-140
erated that provide copious opportunities for PQC141
interference.142
The exogenous provision of preformed fibrils143
(seeded aggregation) bypasses the initial requirement144
for seed formation and allows the rapid incorporation145
of -Syn monomers to their ends [58], presenting146
a more limited number of conformational states at147
which PQC components can interfere. The molecu-148
lar mechanisms of chaperone modulation of -Syn149
aggregation in spontaneous versus seeded aggrega-150
tion are thus likely to differ significantly. Indeed,151
some chaperones interfere with unseeded aggrega-152
tion (e.g., DNAJB6 [60]), whilst others selectively act153
on the elongation of preformed seeds (e.g., HSPB5)154
[61]).155
The distinction between unseeded and seeded156
-Syn aggregation is thus extremely important to157
our understanding of the -Syn aggregation process158
and PQC effects thereon. Cellular studies aimed at159
investigating PQC components in -Syn aggregation160
are most often unable to clearly determine whether161
unseeded, seeded or both processes are targeted and162
to what extent.163
Non-seeded α-Syn aggregation164
It has been surprisingly difficult to consistently165
model spontaneous, non-seeded -Syn aggregation166
in cellular and organismal models. In fact, recent167
nuclear magnetic resonance data showed that -Syn168
at physiological concentrations remains largely in a 169
monomeric, highly dynamic state in cells [4]. Since 170
the crowded cellular environment is expected to facil- 171
itate -Syn aggregation, these data strongly suggest 172
the existence of agents (such as molecular chaperones 173
and protein degradation machineries) that efficiently 174
counteract -Syn aggregation under normal circum- 175
stances. 176
To date, most studies investigating de novo, 177
non-seeded, -Syn aggregation have relied on over- 178
expression of either wildt-type (WT) or mutant 179
variants of -Syn. In one of the earliest models, 180
-Syn inclusion formation was detected in human 181
neuroglioma H4 cells and mouse primary corti- 182
cal neurons only upon overexpression of -Syn 183
constructs (-SynWT,-SynA30P, or-SynA53T) har- 184
boring distinct C-terminal tags of variable sizes, 185
which affected proteasomal clearance [47]. Since 186
untagged -Syn variants remained soluble, the tag 187
potentiated aggregation probably through the expo- 188
sure of the NAC region. Others have employed the 189
co-expression of -Syn with distinct aggregation- 190
prone proteins that co-localize with -Syn in LBs to 191
trigger inclusion formation, such as synphilin-1 [45, 192
62–65] and tubulin polymerization-promoting pro- 193
tein (TPPP/p25) [66], but it is not entirely clear 194
whether these are indeed active drivers of -Syn 195
aggregation. Some studies have also used bimolecu- 196
lar fluorescence complementation assays to assess de 197
novo -Syn aggregation [45, 67, 68]. In these cases, 198
fluorescence is reconstituted and detected upon co- 199
expression of two -Syn constructs fused to either 200
the N-or C-terminus halves of a fluorescent protein 201
(for example, the split Venus-system). However, it 202
is still neither clear whether such assemblies are of 203
fibrillar nature, as the interaction of little as two - 204
Syn molecules is already sufficient to reconstitute 205
fluorescence, nor to what extent the reconstitution 206
of the functional fluorescent protein drives assem- 207
bly. Nevertheless, some degree of -Syn fibrillation 208
was detected upon overexpression of distinct split 209
Venus--Syn in flies [68]. In any case, true detergent- 210
insoluble -Syn aggregates are either usually not 211
observed in unseeded -Syn models, or they com- 212
prise only a small fraction of the total -Syn pool, 213
highlighting the urgent need for better models to doc- 214
ument -Syn aggregation. 215
Seeded α-Syn aggregation 216
Seeded aggregation experiments have been instru- 217
mental in uncovering many of the basic principles 218
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of -Syn pathology (see for instance [26, 69–71]).219
Indeed, most of the -Syn literature relies on exper-220
iments in which an exogenous source of -Syn221
amyloid fibrils is administered to cells or animals222
in order to trigger aggregation of the endogenous -223
Syn (i.e., the -Syn pool generated by cells de novo,224
even if it consists of an artificial transgene). In these225
cases, exogenous -Syn fibrils come from either in226
vitro reactions using recombinant -Syn [69] or from227
fibrils isolated from animal models or human post-228
mortem tissue [19, 26, 72]. As stated above, structural229
differences of -Syn fibrils may lead to different230
synucleinopathies [15, 73]. However, it should be231
noted that there is currently no evidence demonstrat-232
ing that human pathology starts upon exposure to233
exogenous -Syn seeds [36], suggesting that factors234
such as cellular stress may trigger the formation of235
the first -Syn seeds.236
-SYN AGGREGATION AND TOXICITY237
IN THE CONTEXT OF PQC SYSTEMS238
Molecular chaperones239
Suppression of α-Syn aggregation by Hsp70240
machines241
Molecular chaperones are at the heart of several242
PQC pathways and have been extensively impli-243
cated as protective agents against protein aggregation244
and neurodegeneration [74]. Here, we will primar-245
ily focus on the action of Hsp70 machines on -Syn246
aggregation and toxicity. The human genome encodes247
for multiple Hsp70 isoforms and these Hsp70s act248
with the help of many co-factors a system that we249
refer to as the Hsp70 machines.250
Purified Hsp70s (e.g., HSPA1A or HSPA8) alone251
can almost completely block -Syn fibrillation at252
substoichiometric ratios, generating small aggregates253
composed of both proteins [25, 75–77]. Interestingly,254
addition of recombinant Hsp70-interacting protein255
(Hip) to reactions containing Hsp70 and monomeric256
-Syn completely blocked Hsp70 co-aggregation257
and led to sustained inhibition of -Syn aggrega-258
tion in an ATP-dependent manner [78], highlighting259
the importance of additional co-factors for maxi-260
mal suppression of -Syn aggregation by Hsp70261
machines (see below). Purified Hsp70s (HSPA1A262
or HSPA8) have been shown to bind a range of263
-Syn assemblies, including monomers [77], pre-264
fibrillar [76, 78], and fibrillar species [75, 79,265
80]. -Syn amino acid stretches that are bound266
by Hsp70s span residues 10–45 and 97–102 [77].267
Besides the suppression of -Syn nucleation, Hsp70s 268
also bind to -Syn seeds [75] and prevent fibril 269
elongation [79, 80]. These latter findings are con- 270
sistent with a holdase function of Hsp70s against 271
-Syn fibril elongation, possibly shielding fibrillar 272
ends from further incorporation of -Syn molecules 273
[79, 80]. 274
In cells, co-expression of Hsp70 decreased the 275
amount of high molecular weight -Syn species [64, 276
65], probably by stabilization of -Syn in assembly- 277
incompetent states [81]. This could account for 278
decreased cytotoxicity of-Syn upon overexpression 279
of Hsp70 [65, 82]. Indeed, Hsp70 overexpression in 280
primary neurons markedly decreased the size, but not 281
the amount, of secreted -Syn species [82]. Since 282
Hsp70 was also detected in the culture medium, it 283
was proposed to bind monomeric or low molecu- 284
lar weight pre-fibrillar -Syn assemblies and prevent 285
further aggregation into mature fibrils [82]. 286
At the organismal level, mice overexpressing both 287
-Syn and the rat HspA1 showed a 2-fold reduc- 288
tion in 1% Triton-X100-insoluble -Syn-containing 289
aggregates, compared to animals expressing -Syn 290
only [65]. In the fruit fly Drosophila melanogaster, 291
selective expression of -SynWT, -SynA30P, or - 292
SynA53T in dopaminergic neurons for 20 days led to 293
a 50% cell loss, but this could be fully rescued by 294
targeted co-expression of the human Hsp70 isoform 295
HSPA1L [83]. Interestingly, despite its cytoprotective 296
effects, HSPA1L did not inhibit -Syn inclusion for- 297
mation, but rather co-localized with-Syn in LB-like 298
structures, suggesting that Hsp70 binding reduced 299
toxic interactions of -Syn with other biomolecules. 300
Such phenomenon is conserved from flies to humans, 301
with evidence for the accumulation of not only 302
Hsp70, but also its cochaperones Hsp40/DNAJs and 303
Hsp110/NEFs, into LBs and LNs from patients with 304
PD, dementia with Lewy bodies, and other synucle- 305
inopathies [63, 83]. Indeed, the titration of Hsp70s 306
out of solution by misfolded -Syn has been hypoth- 307
esized to contribute to disease onset due to lowering 308
of the functional pool of Hsp70 available for protein 309
quality control pathways [78, 84]. 310
In vitro, the suppression of -Syn aggregation by 311
either Hsp70 (HSPA1A) or Hsc70 (HSPA8) does not 312
require ATP/ADP cycling [25, 75, 78, 80], nor co- 313
chaperones, such as DNAJB1 [78]. In fact, DNAJB1, 314
which stimulates Hsp70 cycling, even counteracts 315
such sequestering activity [76]. However, these fac- 316
tors are essential for the proper function of Hsp70 317
in quality control pathways in vivo [85]. Indeed, 318
overexpression of other members from the family of 319
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Hsp70 co-chaperones also successfully prevents -320
Syn aggregation and/or toxicity in cell and mouse321
models of PD. Of special relevance in this context322
is the large family of Hsp40/DNAJ proteins, which323
are regarded as the main determinants of specificity324
of Hsp70 machines, since different DNAJs bind to325
distinct client proteins and deliver those to Hsp70326
[85, 86]. Thus, DNAJs could be exploited to maxi-327
mize the activity of Hsp70 machines towards specific328
substrates. For example, besides inhibiting -Syn329
aggregation in vitro [76], DNAJB1 almost completely330
abolished -Syn inclusion formation in cells overex-331
pressing -Syn [63]. This has also been shown for332
DNAJB6 and its close homologue DNAJB8 [51],333
both of which also strongly suppress the aggrega-334
tion of other amyloidogenic polypeptides, including335
expanded polyglutamine-containing proteins [60, 87]336
and the amyloid-beta protein [88]. Interestingly, -337
Syn aggregation was not suppressed by a DNAJB6338
mutant that does not interact with Hsp70 [51],339
strengthening the notion that cooperation between340
distinct components of Hsp70 machines is essential341
for optimal function. Despite these examples, little is342
still known on the contribution of different DNAJs343
and/or NEFs to the Hsp70-dependent suppression of344
-Syn aggregation in vivo. Similar to recently devel-345
oped in vitro screens for inhibiting tau aggregation346
[89], or enhancing -Syn disaggregation (see below)347
[90], further comparative studies using distinct com-348
positions of Hsp70 machines are urgently required to349
better understand and manipulate Hsp70 machines in350
synucleinopathies.351
Disaggregation of α-Syn fibrils by Hsp70352
machines353
The diversity and complexity of Hsp70 machines354
is also highlighted by studies investigating the poten-355
tial of these systems to disaggregate pre-existing356
-Syn amyloids. For instance, although Hsp70 alone357
does not modify or disaggregate mature -Syn fibrils358
at relevant time-scales in vitro [75, 91], a specific359
Hsp70/HSPA-Hsp40/DNAJ-Hsp110/NEF combina-360
tion showed powerful, ATP-dependent disaggregase361
activity against-Syn amyloids [90]. Indeed, optimal362
fragmentation and depolymerization of -Syn fibrils363
was detected upon combining Hsc70/HSPA8 with364
Hdj1/DNAJB1 and the NEF Apg2/HSPA4, but not365
upon addition of other Hsp70 machine members, such366
as Hsp70/HSPA1A, DNAJA1, DNAJA2, or BAG1.367
Moreover, a precise stoichiometry between these368
components was crucial for productive disaggrega-369
tion [90, 91], further illustrating the tight balance370
between specificity and levels of chaperones/co- 371
chaperones for the activity of Hsp70 machines. It is 372
still not known whether Hsp70-mediated disaggrega- 373
tion of -Syn also occurs in vivo, but it is tempting 374
to speculate that the breakup of fibrils into smaller, 375
more soluble assemblies facilitates their process- 376
ing by downstream PQC components, as discussed 377
below. However, it is equally possible that disaggre- 378
gation could be detrimental and facilitate -Syn seed 379
propagation. Further studies are necessary to clarify 380
these issues. 381
Clearance of α-Syn assemblies via protein 382
degradation machineries 383
The two major cellular protein degradation 384
machineries comprise the UPS and ALP, with the 385
latter encompassing both autophagosome-dependent 386
and independent pathways [92]. There is an intricate 387
and tightly regulated crosstalk between proteasomal 388
and lysosomal pathways engaged in the processing 389
of -Syn, as several studies reported preferential 390
degradation of -Syn via the UPS or ALP [31, 391
93–98]. Moreover, -Syn (WT or distinct mutants) 392
overexpression can impair the activity of both the 393
UPS [99, 100] and distinct components of the ALP 394
[66, 101–104], which would act in a progressive 395
pathogenic feedback loop to accelerate aggregation 396
and toxicity. Whether UPS or ALP lead to the degra- 397
dation of -Syn assemblies is still actively debated. 398
Recent findings suggest, however, that the UPS has 399
a more prominent role in degrading smaller -Syn 400
assemblies at least when protein quality systems are 401
highly active, as is generally the case in young, 402
healthy organisms [99]. Autophagic activity seems 403
to be more required for larger -Syn assemblies and 404
upon increased -Syn burden, due to either muta- 405
tions that lead to -Syn accumulation or decreased 406
activity of other PQC components, as observed with 407
aging [99]. -Syn has also been shown to be recog- 408
nized and degraded by other cellular (extracellular) 409
proteases not directly linked to the UPS and ALP 410
pathways [105, 106]. However, the extent to which 411
such enzymes are required for proper -Syn turnover 412
and/or inhibition of propagation is still poorly under- 413
stood. 414
PTMs also play a role in -Syn processing and 415
act as important sorting hubs to distinct protein 416
degradation machineries. For instance, the covalent 417
binding of ubiquitin to -Syn, via either mono- 418
(monoUb) or polyubiquitylation (polyUb) in dis- 419
tinct linkage types, has opposing consequences to the 420
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Fig. 2. Targeting and processing of alpha-synuclein (-Syn) by protein quality control (PQC) pathways. Left: in normal conditions, in
which the cellular PQC capacity is in balance with the -Syn burden, soluble as wells as pre-fibrillar -Syn assemblies (after disassembly)
have been shown to be targeted to and degraded by several PQC components. The initial survey of -Syn species might be performed by
molecular chaperones (1), which can facilitate the sorting of -Syn to distinct degradative routes, such as the ubiquitin-proteasome system
(UPS; 2), a ubiquitin-independent proteasomal degradation pathway (3), chaperone-mediated autophagy (CMA; 4), macroautophagy (5),
secretion via endosomes (6) [162], and proteolytic digestion by intracellular (7) or extracellular proteases. Right: in aged organisms or
pathological conditions, the -Syn burden surpasses the cellular PQC capacity, leading to -Syn accumulation and subsequent aggregation.
Fibrillar -Syn assemblies can trap several biomolecules, including molecular chaperones (8), which contributes to chaperone depletion and
decreases PQC capacity. Similarly,-Syn aggregation has been linked to impairment of different steps of macroautophagy (9), CMA (10), and
proteasomal degradation (11). In some experimental setups, increased -Syn levels can also lead to increased autophagic flux and destruction
of organelles, such as mitochondria (12). -Syn species can also be secreted to the extracellular space and taken up by neighboring cells (13),
where they seed the aggregation of soluble -Syn species (14). -Syn aggregation additionally impairs the intracellular trafficking of other
proteins, such as the lysosomal enzyme glucocerebrosidase (GCase; 15). Decreased lysosomal GCase activity, due to either mislocalization
of wildtype (wt) GCase or mutant GCase variants (16), leads to accumulation of GCase substrates (such as glycosylceramide; 17), which
might potentiate -Syn aggregation. See main text for further mechanistic details and references. ER: endoplasmic reticulum; Hsc70: heat
shock cognate 71 kDa protein; LAMP2a: lysosome-associated membrane protein 2 isoform a; poly-Ub: poly-ubiquitin.
fate of -Syn. For instance, the co-chaperone CHIP421
(carboxyl terminus of Hsp70-interacting protein),422
a ubiquitous E3 Ub-ligase and crucial downstream423
effector of Hsp70 machineries [85], was shown to424
promote -Syn degradation via both the UPS and425
ALP [107]. Also, while monoubiquitylation by the426
E3 ubiquitin-ligase SIAH targeted -Syn to the UPS,427
removal of the ubiquitin moiety by the deubiquitylase428
USP9X favored -Syn degradation via macroau-429
tophagy [108]. Yet another ubiquitin-ligase (Nedd4)430
facilitated the binding of K63-linked polyUb chains431
to -Syn and promoted its lysosomal degradation432
via the ESCRT pathway [109]. Depending on its433
assembly state, other PTMs such as SUMOylation,434
phosphorylation, nitration, O-GlcNAcylation, oxida-435
tion, and dopamine-modification can also modulate436
-Syn processing via downstream degradation path- 437
ways [30, 31, 110–114]. In this context, the main 438
findings associated to the partition of -Syn between 439
the UPS and ALP are discussed below and illustrated 440
in Fig. 2. 441
Ubiquitin-proteasome system 442
In mammalian cells, the central player of the UPS 443
is the 26S proteasome, a large, ATP-dependent multi- 444
protein complex devoted to the selective destruction 445
of target proteins [115]. Evidence for the degrada- 446
tion of -Syn via proteasomes comes from both 447
in vitro [116] and cellular studies [117–119], with 448
not only monomeric, but maybe also pre-fibrillar - 449
Syn species (after dissociation) being targeted to this 450
pathway [30, 100]. Several Ub-ligases interact with 451
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-Syn and catalyze the addition of either mono- or452
polyUb chains with either cytoprotective or toxic con-453
sequences depending on the specific experimental454
setup, presumably due to differential impact on cellu-455
lar -Syn half-life [109, 117, 120, 121]. Unmodified456
-Syn can also be degraded by proteasomes via an457
Ub-independent pathway [118], particularly relevant458
for phosphorylated -Syn at serine 129 (-SynpS129)459
[119]. A mutant mimicking-SynpS129 (-SynS129E)460
was shown to be a poor autophagic substrate [111],461
re-emphasizing the complementary importance of the462
different degradation pathways. Several lines of evi-463
dence also suggest that an increased -Syn burden464
inhibits proteasomal activity, which in turn might465
lead to a further increase in -Syn levels, thus estab-466
lishing a pathogenic feedback loop favoring -Syn467
aggregation [100, 104, 122, 123].468
Autophagy-lysosome pathway469
The numerous reports on -Syn degradation via470
the ALP highlight the importance of lysosomal-471
dependent regulation of -Syn levels [124]. Not472
surprisingly, a plethora of therapeutic strategies473
targeting the ALP have been explored to tackle -474
Syn aggregation and toxicity (reviewed in [125]).475
The ALP comprises catabolic processes that con-476
verge at the lysosome, being usually divided477
in three distinct types: macroautophagy, microau-478
tophagy, and chaperone-mediated autophagy (CMA)479
[126]. Macroautophagy relies on the engulfment480
of substrates within autophagosomes, which are481
double-layered membrane vesicles that sequester482
intracellular components and target them to lyso-483
somes for degradation [127]. Most long-lived484
proteins, protein aggregates and even whole damaged485
organelles are degraded via macroautophagy [92,486
128]. The importance of macroautophagy for nor-487
mal cellular function is exemplified by experiments488
in which loss of macroautophagy in neurons led to489
accumulation of ubiquitylated proteins and inclu-490
sion bodies, and neurodegeneration [129]. Moreover,491
mutations in different autophagy-related genes, such492
as ATG5, lead to genetic diseases with neurologic493
phenotypes in humans [130].494
Data supporting a role for macroautophagy in495
the degradation of monomeric and pre-fibrillar -496
Syn assemblies come mainly from studies detecting497
-Syn buildup upon exposure of cell lines over-498
expressing either WT or mutant -Syn variants499
to the inhibitor of autophagosome formation 3-500
methyladenine [93, 95, 97, 131]. In vivo, overexpres-501
sion of beclin-1, which is involved in autophagosome502
formation via the phosphatidylinositol 3-phosphate 503
kinase complex, rescued neurological deficits of - 504
Syn transgenic mice [131]. Yet, beclin-1 is involved 505
in other endosomal pathways, not directly linked to 506
macroautophagy [132], which may contribute to the 507
reduction of -Syn levels and improved performance 508
of animals overexpressing -Syn [131]. Impairment 509
of lysosomes, toward which all ALP components 510
converge, with bafilomycin A1 also resulted in-Syn 511
buildup, further supporting a role for the ALP in - 512
Syn degradation [96, 125, 133, 134]. Nonetheless, 513
whether macroautophagy is capable of degrading 514
aggregated, insoluble -Syn assemblies, such as 515
those present in LBs, is still debated. For instance, in 516
a cell model of endogenous -Syn aggregation upon 517
exposure to exogenous -Syn pre-formed fibrils, - 518
Syn inclusion resisted lysosomal degradation [134]. 519
In addition, increasing macroautophagy flux upon 520
-Syn overexpression was also shown to have detri- 521
mental effects, ranging from increased degradation of 522
mitochondria (mitophagy) in both cellular [135], and 523
animal models of PD [136] to enhanced secretion of 524
-Syn assemblies to the extracellular space [66], that 525
may contribute to the spreading of pathogenic -Syn 526
aggregates. On the other hand, Gao and colleagues 527
(2019) have recently demonstrated enhanced degra- 528
dation of internalized exogenous -Syn pre-formed 529
fibrils in neuronal cell lines upon treatment with dif- 530
ferent autophagy inducers, suggesting that lysosomes 531
might be capable of clearing seeded fibrillar -Syn 532
[137]. 533
Different from macroautophagy, CMA encom- 534
passes the selective targeting of substrates to lyso- 535
somes via Hsc70 (HSPA8) and its co-chaperones, to 536
specifically recognize cargo proteins with a KFERQ- 537
like pentapetide motif, and lysosomal-associated 538
membrane protein 2a (LAMP2a)-mediated substrate 539
translocation across lysosomal membranes [138, 540
139]. Several lines of evidence support the involve- 541
ment of CMA in the processing of -Syn [125]. 542
In an in vitro lysosomal reconstitution assay, - 543
SynWT was selectively targeted to lysosomes by 544
LAMP2a, and mutations within a KFERQ-like motif 545
in -Syn C-terminus abolished this activity [94]. 546
In cultured cells overexpressing -Syn, macroau- 547
tophagy inhibition led to higher -Syn clearance 548
via CMA [95, 140], while -Syn protein levels 549
were increased upon specific knockdown of LAMP2a 550
[141], or HSPA8 [141, 142]. Compared to healthy 551
controls, lower LAMP2a protein levels were detected 552
in brains from early-stage PD patients, accompanied 553
by a buildup of -Syn and other known CMA sub- 554
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strates, such as myocyte-specific enhancer factor 2D555
(MEF2D) and nuclear factor of kappa light polypep-556
tide gene enhancer in B-cells inhibitor alpha (IκB)557
[143]. The importance of CMA in processing -Syn558
monomers and dimers, but not pre-fibrillar assem-559
blies [111], is somewhat diminished by the finding560
that -Syn steady-state levels were unchanged in561
Lamp2 knockout mice [144]. This however may be562
due to developmental adaptations in other PQC com-563
ponents, such as the UPS, as outlined above, thus564
masking the influence of CMA. Indeed, in vivo down-565
regulation of Lamp2a in rats resulted in accumulation566
of ubiquitin-positive-Syn inclusions in the substan-567
tia nigra followed by loss of dopaminergic neurons568
[145]. Additional evidence for CMA involvement569
in -Syn degradation comes from observations that570
distinct PTMs, including oxidation, nitration, and571
modification by oxidized dopamine, impair -Syn572
degradation via CMA, resulting in its buildup [111].573
Importantly, similar to the rare -SynA30P and -574
SynA53T mutations [94], dopamine-modified -Syn575
(present in sporadic PD cases) also interferes with576
the processing of other CMA substrates [111],577
further contributing to the imbalance of protein578
homeostasis.579
Upon convergence of distinct ALP routes at lyso-580
somes, soluble -Syn assemblies can be degraded581
by acidic proteases, such as cathepsin D [146–148].582
Another lysosomal enzyme that has attracted much583
attention in synucleinopathies is glucocerebrosi-584
dase (GCase). While homozygous mutations in the585
GCase-encoding geneGBA1 cause Gaucher’s disease586
[149], heterozygous mutations are a well-established587
risk factor for developing PD [150]. Indeed, -Syn588
buildup is observed in several models of GCase defi-589
ciency. This occurs upon pharmacological inhibition590
of GCase activity in cultured cells [151, 152] and591
also in GBA1 mutant backgrounds, both in mouse592
models overexpressing -Syn [153–155] and in593
PD patient iPS-derived dopaminergic neurons [156,594
157]. -Syn buildup impairs GCase trafficking and595
targeting to lysosomes [158, 159]. Conversely, rescue596
of GCase activity in mice overexpressing -SynA53T597
reduced -Syn levels and toxicity [155], establish-598
ing a pathogenic feedback loop that promotes loss599
of GCase function, and -Syn accumulation, aggre-600
gation and, potentially, cell-to-cell transmission of601
-Syn seeds [160, 161]. Altogether, these results602
suggest that the upregulation of autophagy without603
a simultaneous improvement of lysosomal capacity604
might not be a true therapeutic strategy in synucle-605
inopathies.
CONCLUDING REMARKS 606
The topics discussed here paint a complex picture 607
of cellular strategies engaged in the tight regulation 608
of -Syn protein levels, which ultimately determine 609
its aggregation propensity and associated toxicity. 610
Even though there are still some fundamental gaps 611
in our understanding of -Syn biology, it has become 612
increasingly clear that the activity of dedicated PQC 613
components, such as molecular chaperones, the UPS, 614
and ALP is a crucial line of defense against - 615
Syn-mediated pathology. Failure of these systems 616
(e.g., due to cellular stress, genetic predisposition, 617
or aging) will influence -Syn levels and solubility, 618
eventually leading to disease. However, it is tempt- 619
ing to envision that novel therapeutic strategies to 620
prevent, slow down and/or halt progression of synu- 621
cleinopathies will emerge based on our understanding 622
of protein homeostasis in general and in particular in 623
components that prevent initiation of -Syn protein 624
aggregation or help clearing them before they affect 625
neuronal health and synaptic integrity. 626
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